Evaluation of the efficacy of the Bangladeshi version of Pralsetinib and its differences with the original drug

Pralsetinib is an oral selective RETtyrosine kinase inhibitor, mainly used to treat RETfusion-positive non-small cell lung cancer (NSCLC) and RET mutated thyroid cancer. The Bangladeshi version of Platinib is a generic version of the original drug launched in the Bangladeshi market. Its main purpose is to improve drug accessibility and reduce patients’ economic burden.

Clinical and real-world data show that the Bangladeshi version of platinib has similar objective response rate (ORR) and disease control rate (DCR) to the original drug in RETfusion-positive NSCLC patients. Most patients' symptoms improved significantly and their tumor burden was reduced within a few weeks to several months of use, showing that the generic drug is reliable in efficacy.

The Bangladeshi version is completely consistent with the original drug in terms of chemical composition and mechanism of action, but there may be differences in the production process, excipients and drug registration standards. In addition, since original drugs are usually verified through rigorous clinical trials, although generic drugs have been approved by regulatory authorities in terms of efficacy and safety, they may be less verified in long-term clinical data and special patient groups. In terms of price, the Bangladeshi version of Platinib is generally more affordable, helping more patients gain access to treatment.

For patients with limited financial conditions or inaccessible original drugs, the Bangladeshi version of platinib provides a feasible alternative. When prescribing generic drugs, doctors should pay attention to the reliability of drug sources, dosage accuracy and individual patient tolerance. Through rational use and monitoring, the Bangladeshi version of platinib can significantly reduce treatment costs and expand treatment coverage for RET-driven cancer patients while ensuring efficacy.

Reference link:https://www.drugs.com